Xiaoyu Wen

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin, Feng Bi, Shanzhi Gu et al. · Journal of Clinical Oncology · 2021 · 414 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Hepatitis C Virus Nonstructural Protein 5A Modulates the Toll-Like Receptor-MyD88-Dependent Signaling Pathway in Macrophage Cell Lines

Takayuki Abe, Yuuki Kaname, Itsuki Hamamoto et al. · Journal of Virology · 2007 · 167 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Baculovirus Induces Type I Interferon Production through Toll-Like Receptor-Dependent and -Independent Pathways in a Cell-Type-Specific Manner

Takayuki Abe, Yuuki Kaname, Xiaoyu Wen et al. · Journal of Virology · 2009 · 84 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma

Weijian Sun, Bin He, Beng Yang et al. · Laboratory Investigation · 2018 · 53 citations · Full text

Life Sciences, Molecular Biology, Oncology +16